Compare AbCellera Biologics Inc (ABCL) vs Live Nation Entertainment, Inc. (LYV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Live Nation Entertainment, Inc. — how do they compare? AbCellera Biologics Inc trades at $7.18 (market cap $2.35B), while Live Nation Entertainment, Inc. trades at $181.37 (market cap $42.80B). The key difference: Live Nation Entertainment, Inc. is far larger — about 18.2× AbCellera Biologics Inc's market cap. Which is the better fit depends on your goals.
| ABCL | LYV | |
|---|---|---|
Market Cap | $2.35B | $42.80B |
Sector | Health | Industrials |
52-Week High | $8.12 | $186.59 |
52-Week Low | $2.78 | $125.61 |
Enterprise Value | $1.99B | $44.31B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Live Nation (LYV) trades at $183.92, down 1.43% with a bullish technical signal despite recent earnings misses. The stock shows strong analyst support with 88.6% buy ratings and a $194 consensus target. Revenue growth remains solid at $25.2B for 2025, though profitability metrics are weak with a 0.33% net margin and negative ROE. Recent news highlights strong concert demand and strategic initiatives.
Outlook remains positive driven by live event recovery and ticketing dominance, but elevated valuation ratios and profitability challenges present risks. The stock faces headwinds from legal expenses and consumer spending pressures, requiring careful monitoring of execution against growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →
